Who are Vantas's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Yselty, Orgovyx, Orilissa, Firmagon, Plenaxis, Cetrotide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/histrelin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Vantas — Competitive Intelligence Brief

Vantas (HISTRELIN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Gonadotropin Releasing Hormone Receptor Agonist. Area: Oncology.

marketed Gonadotropin Releasing Hormone Receptor Agonist Gonadotropin-releasing hormone receptor Oncology Recombinant protein Live · refreshed every 30 min

Target snapshot

Vantas (HISTRELIN). Vantas works by binding to the gonadotropin-releasing hormone receptor, mimicking the natural hormone and reducing the production of sex hormones.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vantas TARGET	HISTRELIN		marketed	Gonadotropin Releasing Hormone Receptor Agonist	Gonadotropin-releasing hormone receptor	1991-01-01
Yselty	LINZAGOLIX	Obseva Ireland Ltd	marketed		Gonadotropin-releasing hormone receptor	2022-01-01
Orgovyx	relugolix	MYOVANT SCIENCES	marketed	Gonadotropin Releasing Hormone Receptor Antagonist [EPC]	Gonadotropin-releasing hormone receptor	2020-01-01
Orilissa	ELAGOLIX	AbbVie	marketed	Gonadotropin Releasing Hormone Receptor Antagonist	Gonadotropin-releasing hormone receptor	2018-01-01
Firmagon	degarelix	Ferring	marketed	Gonadotropin Releasing Hormone Receptor Antagonist	Gonadotropin-releasing hormone receptor	2008-01-01
Plenaxis	ABARELIX	Speciality European	marketed	abarelix	Gonadotropin-releasing hormone receptor	2003-01-01
Cetrotide	CETRORELIX	Merck KGaA	marketed	Gonadotropin Releasing Hormone Receptor Antagonist	Gonadotropin-releasing hormone receptor	2000-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2036-02-25 — Orgovyx · 10350170 · US
2037-09-29 — Orgovyx · 10449191 · US
2037-09-29 — Orgovyx · 11583526 · US
2037-09-29 — Orgovyx · 11033551 · US
2037-09-29 — Orgovyx · 10786501 · US

Sponsor landscape (Gonadotropin Releasing Hormone Receptor Agonist class)

Accord Healthcare S.L.U. · 2 drugs in this class
Tersera · 2 drugs in this class
· 1 drug in this class
Pfizer · 1 drug in this class
Verity · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vantas — Competitive Intelligence Brief. https://druglandscape.com/ci/histrelin. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab